EUCTR2016-001754-18-ES进行中（未招募）1 期
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Sun Pharma Advanced Research Company (SPARC) Limited0 个研究点目标入组 89 人开始时间: 2019年6月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 89
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Willing and able to give written/signed, and dated, informed consent (or by legally acceptable representative/impartial witness when applicable) and is available for the entire study
- •2.Willing and able to comply with the scheduled visits, treatment plan, laboratory testing, study procedures, and restrictions, and be accessible for follow-up
- •3.Subjects with CML in any phase or Ph+ ALL who are resistant and/or intolerant to = 3 prior TKIs or are not eligible for 3rd TKI [e.g.: due to comorbidities, hypersensitivity to excipients, resistance/intolerance to at least 2 TKIs other than imatinib) or the TKIs are ineffective against mutations detected in the patient’s tumor)]
- •4.Male or female aged = 18 years
- •5.Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- •6.Adequate organ and immune system function as indicated by the following laboratory values obtained = 2 weeks prior to IMP administration.
- •7.Subjects of childbearing potential must practice a medically acceptable method of birth control as judged by the Investigator (refer to protocol for details)
- •8.Male subjects enrolled in the study should not father a child and are advised to prevent passage of semen to their sexual partner during intercourse using an acceptable method as detailed in the Inclusion criteria # 7 and judged by the Investigator for the duration of the study and for 3 months after the last IMP administration
- •9.Female subjects of childbearing potential must have a negative pregnancy test (as confirmed by a negative urine pregnancy test with a sensitivity of less than 50 mIU/mL or equivalent units of human chorionic gonadotropin).
- •10.Female subjects should be non-lactating and non-breast-feeding
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 42
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 41
排除标准
- •1.Presence of T315I mutations
- •2.Any major surgery, as determined by the Investigator, within 14 days of IMP administration
- •3.Inability to swallow oral medication
- •4.Evidence of clinically significant organ dysfunction or any clinically relevant deviation from normal in physical examination, ECG findings, vital signs, or clinical laboratory test findings which in the opinion of the investigator may jeopardize the safety of the patient during the study or may interfere with the evaluation of the study medication.
- •5.Positive exclusion tests: urine pregnancy tests (if applicable), HIV
- •6.History of any relevant allergy/hypersensitivity (including known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the IMP or its excipients)
- •7.Known history of active hepatitis B or hepatitis C
- •8.Received an investigational agent within 30 days of IMP administration
- •9.Subjects on sensitive substrates of CYP2C8 with a narrow therapeutic index, or on strong inhibitors or inducers of major CYP enzymes, should be avoided or used with caution in this trial
- •10.Use of concomitant medication that might influence the results of the study prior to IMP administration/or anticipated need any time during the study
- •11.Known or suspected history of significant drug or alcohol abuse as judged by the Investigator
- •12.Radiotherapy within 21 days or cytotoxic chemotherapy or Vincristine within 7 days (for Ph+ ALL only); interferon or Cytarabine or immunotherapy within 14 days prior to the first IMP administration visit
- •13.Active central nervous system (CNS) disease as evidenced by cytology or pathology.
- •14.Malabsorption syndrome or other illness that could affect oral absorption of the IMP
- •15.Clinically significant, uncontrolled, or active cardiovascular disease
- •16.Uncontrolled intercurrent illness
- •17.Subjects eligible and willing to undergo bone marrow transplant
- •18.Autologous or allogeneic stem cell transplant = 3 months prior to Screening
- •19.Another primary malignancy within the past 3 years or earlier.
- •20.Any contraindications for repeated bone marrow sample collection
- •21.Prior exposure to K0706 therapy as a participant in Part B of the protocol
- •Other criteria may apply (refer to protocol)
研究者
相似试验
进行中（未招募）
1 期
Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706 in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)MedDRA version: 21.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: PTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2016-001754-18-ROSun Pharma Advanced Research Company (SPARC) Limited255
进行中（未招募）
1 期
Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706 in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaEUCTR2016-001754-18-HUSun Pharma Advanced Research Company (SPARC) Limited255
进行中（未招募）
1 期
Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706 in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaEUCTR2016-001754-18-BESun Pharma Advanced Research Company (SPARC) Limited255
进行中（未招募）
1 期
Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706 in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)MedDRA version: 19.1 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemia System Organ Class: 100000004864MedDRA version: 19.1 Level: LLT Classification code 10009015 Term: Chronic myeloid leukemia System Organ Class: 100000004864MedDRA version: 19.1 Level: PT Classification code 10034877 Term: Philadelphia chromosome positive System Organ Class: 10022891 - InvestigationsEUCTR2016-001754-18-CZSun Pharma Advanced Research Company Ltd.110
进行中（未招募）
1 期
Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706 in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaEUCTR2016-001754-18-GBSun Pharma Advanced Research Company (SPARC) Limited255